Loading...
01/11 12:22
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reveals several concerning financial metrics, including declining net sales, gross margins, and adjusted net income. While there are positive developments like the new Indianapolis facility and reduced borrowings, the overall sentiment is negative due to weak financial performance and conservative guidance. The Q&A session highlighted management's reluctance to provide detailed guidance and clarity on certain issues, which adds uncertainty. Despite some optimism in the Medical CMO space, the decline in other sectors and lack of strong positive catalysts lead to a negative outlook.
Net Sales $375 million, a 10% decline year-over-year when excluding the AT&M business divested earlier this fiscal year.
Medical Net Sales $115 million, up 2% year-over-year, driven by non-recurring consignment inventory sales to a major customer.
Automotive Net Sales $173 million, a 14% decrease year-over-year, primarily due to declines in North America.
Industrial Net Sales $86 million, down 15% year-over-year, with declines across all regions.
Gross Margin Rate 7.2%, a 70 basis point decline from 7.9% in Q3 of fiscal 2024, driven by consigned inventory sales and lower absorption.
Adjusted Selling and Administrative Expense $11.2 million, a $3.6 million or 24% reduction year-over-year, primarily due to the absence of AT&M expenses and cost reduction efforts.
Adjusted Operating Income $15.7 million or 4.2% of net sales, compared to $18.7 million or 4.4% of net sales last year.
Other Income and Expense Expense of $4.6 million, down from $6.3 million last year, driven by lower interest expense.
Effective Tax Rate 46.6%, compared to 52.4% in Q3 of fiscal 2024, primarily due to limitations on interest expense deductibility.
Adjusted Net Income $6.8 million or $0.27 per diluted share, compared to $9.8 million or $0.39 per diluted share last year.
Cash and Cash Equivalents $51.4 million as of March 31, 2025.
Cash Flow from Operating Activities $30.9 million, marking the fifth consecutive quarter of positive cash flow.
Cash Conversion Days 99 days, improved from 110 days in Q3 of fiscal 2024.
Inventory $296.6 million, down $100 million or 25% year-over-year.
Capital Expenditures $4 million in Q3, expected to be at the low end of the guidance range.
Borrowings $178.8 million, down $116 million or 40% from the beginning of the fiscal year.
Share Repurchase $3 million spent to repurchase 175,000 shares, totaling $100.7 million returned to shareholders since October 2015.
New Manufacturing Facility: Addition of a new manufacturing facility in Indianapolis focused on the medical industry, representing 300,000 square feet, to support production of medical disposables, surgical instruments, and selected drug delivery devices.
Cash Flow: Generated $30.9 million in cash flow from operating activities, marking the fifth consecutive quarter of positive cash flow.
Debt Reduction: Borrowings reduced by $116 million or 40% from the beginning of the fiscal year, now totaling $178.8 million.
Inventory Management: Inventory reduced by $100 million or 25% year-over-year, ending at $296.6 million.
Cost Reduction: Adjusted selling and administrative expenses decreased by 24% year-over-year to $11.2 million.
Repositioning Strategy: Reiterating guidance for fiscal 2025, focusing on organic growth in the medical CMO sector and reallocating cash from EMS operations to support this strategy.
Tariff Environment: The current tariff environment is filled with uncertainty and unpredictability, impacting the business, customers, and end consumers. Potential solutions include changing delivery locations, shifting production, or absorbing tariffs.
Supply Chain Challenges: There may be impacts on the supply chain, and alternatives for U.S. manufacturing are being considered. The uncertainty complicates the timing of recovery in the core EMS business.
Market Share Loss: Customers in the Industrial vertical are experiencing market share loss due to the commoditization of smart meters and reductions in climate control and public safety products.
Economic Factors: The company is navigating an environment of uncertainty, which affects sales and margins, particularly in the Automotive and Industrial sectors.
Regulatory Issues: The increase in Medical sales was driven by non-recurring consignment inventory sales related to an FDA recall, indicating potential regulatory risks.
Operational Challenges: The company is closing the Tampa facility to streamline operations, which involves exit costs estimated between $6.5 million to $8.5 million.
New Manufacturing Facility: Addition of a new manufacturing facility in Indianapolis focused on the medical industry to expand presence as a medical CMO.
CMO Strategy: Strategically utilizing cash generated from EMS operations to redeploy capital to the CMO, with a focus on organic and potentially inorganic growth.
Divestiture of AT&M Business: Divested the non-core AT&M business to streamline operations and focus on core competencies.
Workforce and Cost Reductions: Implemented major workforce and cost reductions to respond to demand softness.
Inventory and Cash Flow Improvements: Significant improvements in inventory management and cash flow generation.
Focus on Medical Technologies: Repositioning the company to focus on emerging medical technologies and high-level assemblies.
Fiscal 2025 Sales Guidance: Reiterating guidance for fiscal 2025 with net sales expected in the range of $1.4 billion to $1.44 billion.
Adjusted Operating Income Guidance: Adjusted operating income estimated at 3.4% to 3.6% of net sales.
Capital Expenditures Guidance: Capital expenditures expected to be in the range of $40 million to $50 million.
Tax Rate Expectation: Expecting an effective tax rate around 30% for the full fiscal year.
Exit Costs for Tampa Facility: Total exit costs for the closure of the Tampa facility estimated in the range of $6.5 million to $8.5 million.
Share Repurchase Program: In the third quarter, Kimball Electronics invested $3 million to repurchase 175,000 shares of common stock. Since October 2015, a total of $100.7 million has been returned to shareholders through the purchase of 6.5 million shares. There is $19.3 million remaining on the repurchase program.
The earnings call highlights a mix of positive and negative factors. Strong adjusted income and net income, debt reduction, and cash flow are positives. However, the guidance for fiscal 2026 indicates revenue decline and modest growth in key segments. The Q&A reveals positive sentiment towards medical growth and strategic acquisitions, but concerns in the automotive sector and potential SG&A increase. Overall, the outlook is mixed with stable margins and strategic growth plans, leading to a neutral sentiment.
The earnings call highlights a robust strategy with new facility expansion, strong focus on the medical segment, and margin improvement efforts. The Q&A reveals positive sentiment towards automation and growth initiatives, despite some vague responses on industrial plans. The reiteration of fiscal guidance, coupled with strategic investments in sales and business development, supports a positive outlook. The absence of negative financial surprises and the focus on high-growth segments suggest a positive stock price movement in the short term.
The earnings call reveals several concerning financial metrics, including declining net sales, gross margins, and adjusted net income. While there are positive developments like the new Indianapolis facility and reduced borrowings, the overall sentiment is negative due to weak financial performance and conservative guidance. The Q&A session highlighted management's reluctance to provide detailed guidance and clarity on certain issues, which adds uncertainty. Despite some optimism in the Medical CMO space, the decline in other sectors and lack of strong positive catalysts lead to a negative outlook.
The earnings call highlights declining sales, operational challenges, and market uncertainties. Despite debt reduction and a share repurchase program, the significant drop in net sales and broad-based demand softness weigh heavily. The Q&A section reveals management's evasiveness on key issues, adding to investor concerns. The restructuring plan and focus on new markets may offer future growth, but current conditions suggest a negative outlook.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
